WO2001017614A3 - Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents - Google Patents

Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents Download PDF

Info

Publication number
WO2001017614A3
WO2001017614A3 PCT/IB2000/001427 IB0001427W WO0117614A3 WO 2001017614 A3 WO2001017614 A3 WO 2001017614A3 IB 0001427 W IB0001427 W IB 0001427W WO 0117614 A3 WO0117614 A3 WO 0117614A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antineoplastic agents
compositions containing
maleimide derivatives
containing succinimide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/001427
Other languages
French (fr)
Other versions
WO2001017614A2 (en
Inventor
Dominique P Bridon
Roger Leger
Xicai Huang
Peter G Milner
Damon Smith
Alan M Ezrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Priority to JP2001521398A priority Critical patent/JP2003508502A/en
Priority to EP00962764A priority patent/EP1212120A2/en
Priority to AU74404/00A priority patent/AU7440400A/en
Priority to CA002383794A priority patent/CA2383794A1/en
Publication of WO2001017614A2 publication Critical patent/WO2001017614A2/en
Publication of WO2001017614A3 publication Critical patent/WO2001017614A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)

Abstract

Derivatives of antineoplastic agents are prepared. The derivatives are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
PCT/IB2000/001427 1999-09-07 2000-09-07 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents Ceased WO2001017614A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001521398A JP2003508502A (en) 1999-09-07 2000-09-07 Methods and compositions for the production of long-lasting antineoplastic agents
EP00962764A EP1212120A2 (en) 1999-09-07 2000-09-07 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
AU74404/00A AU7440400A (en) 1999-09-07 2000-09-07 Methods and compositions for producing long lasting antineoplastic agents
CA002383794A CA2383794A1 (en) 1999-09-07 2000-09-07 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15268199P 1999-09-07 1999-09-07
US60/152,681 1999-09-07

Publications (2)

Publication Number Publication Date
WO2001017614A2 WO2001017614A2 (en) 2001-03-15
WO2001017614A3 true WO2001017614A3 (en) 2002-02-28

Family

ID=22543945

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2000/001427 Ceased WO2001017614A2 (en) 1999-09-07 2000-09-07 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
PCT/IB2000/001429 Ceased WO2001017568A2 (en) 1999-09-07 2000-09-07 Bioconjugation in vivo to pulmonary or blood components

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001429 Ceased WO2001017568A2 (en) 1999-09-07 2000-09-07 Bioconjugation in vivo to pulmonary or blood components

Country Status (5)

Country Link
EP (2) EP1235618A2 (en)
JP (2) JP2003508501A (en)
AU (3) AU7440400A (en)
CA (2) CA2383794A1 (en)
WO (2) WO2001017614A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ATE396202T1 (en) 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc LONG ACTING GLUCAGONE-LIKE PEPTIDE-2 FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US6759029B2 (en) 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
JP2005503425A (en) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
DK1479691T3 (en) 2001-05-31 2007-03-12 John Erickson Long-acting Fuion Peptide Inhibitors for HIV Infection
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
SG165988A1 (en) * 2001-11-29 2010-11-29 Theracos Inc Compounds for treatment of inflammation, diabetes and related disorders
AU2003246500A1 (en) * 2002-07-31 2004-02-16 Conjuchem Biotechnologies Inc. Long lasting natriuretic peptide derivatives
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US9006388B2 (en) * 2003-03-26 2015-04-14 Sudhir Paul Covalent attachment of ligands to nucleophilic proteins guided by non-covalent
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
DE10356346A1 (en) * 2003-11-28 2005-06-23 TransMIT Gesellschaft für Technologietransfer mbH Invention relating to the prophylaxis and therapy of diseases caused by or caused by thrombus formation
AU2004294989B2 (en) * 2003-12-01 2009-03-19 Ignasi Carrio Novel differential imaging method
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP2246086A3 (en) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heating unit
EP2374480A3 (en) * 2005-08-19 2013-05-01 Endocyte, Inc. Mutli-drug ligand conjugates
CN100475270C (en) 2006-01-20 2009-04-08 清华大学 Medicine for treating tumor and application thereof
CN101002945B (en) 2006-01-20 2012-09-05 清华大学 Novel complex used for treating tumor
US7982018B2 (en) 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
CN101219219B (en) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 Complex containing vascellum chalone or fragment, preparation method and application thereof
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
CN101754747A (en) * 2007-06-05 2010-06-23 Paka肺部医药公司 Methods and compositions for delivering drugs to the lungs
EP2370068A4 (en) 2008-12-10 2015-09-23 Paka Pulmonary Pharmaceuticals Inc Methods and compositions for delivery of medicaments to the lungs
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
AU2019237507B2 (en) 2018-03-23 2025-04-03 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
JP7620569B2 (en) * 2019-05-06 2025-01-23 セーキョー Novel therapeutic vectors and prodrugs for cancer treatment
CN111138435A (en) * 2020-01-08 2020-05-12 宜昌博仁凯润药业有限公司 Modified methotrexate and preparation method and application thereof
IL308392A (en) 2021-05-13 2024-01-01 Carmot Therapeutics Inc Modulators of g-protein coupled receptors
CN117551062B (en) * 2023-11-07 2025-12-16 江苏吉贝尔药业股份有限公司 Taxane derivative and preparation method and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62138430A (en) * 1985-12-12 1987-06-22 Teijin Ltd Production of conjugate of methotrexate with protein
JPH01211530A (en) * 1988-02-16 1989-08-24 Pola Chem Ind Inc Antitumor agent
DE4122210A1 (en) * 1991-07-04 1993-01-14 Deutsches Krebsforsch CONJUGATES OF TUMORACTIVE COMPOUND AND PROTEIN AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
WO1995010302A1 (en) * 1993-10-15 1995-04-20 Redcell, Inc. Cellular and serum protein anchors and conjugates
WO1997023243A1 (en) * 1995-12-22 1997-07-03 Bristol-Myers Squibb Company Branched hydrazone linkers
WO1998000171A2 (en) * 1996-07-01 1998-01-08 Conjuchem, Inc. Conjugates of thrombin inhibitors and endogenes carriers
WO1998010794A2 (en) * 1996-09-11 1998-03-19 Felix Kratz Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO2000076551A2 (en) * 1999-06-09 2000-12-21 Ktb Tumorforschungs Gmbh Method for producing an injectable medicament preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3220180B2 (en) * 1991-05-23 2001-10-22 三菱化学株式会社 Drug-containing protein-bound liposomes
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
AU739028B2 (en) * 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62138430A (en) * 1985-12-12 1987-06-22 Teijin Ltd Production of conjugate of methotrexate with protein
JPH01211530A (en) * 1988-02-16 1989-08-24 Pola Chem Ind Inc Antitumor agent
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
DE4122210A1 (en) * 1991-07-04 1993-01-14 Deutsches Krebsforsch CONJUGATES OF TUMORACTIVE COMPOUND AND PROTEIN AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
WO1995010302A1 (en) * 1993-10-15 1995-04-20 Redcell, Inc. Cellular and serum protein anchors and conjugates
WO1997023243A1 (en) * 1995-12-22 1997-07-03 Bristol-Myers Squibb Company Branched hydrazone linkers
WO1998000171A2 (en) * 1996-07-01 1998-01-08 Conjuchem, Inc. Conjugates of thrombin inhibitors and endogenes carriers
WO1998010794A2 (en) * 1996-09-11 1998-03-19 Felix Kratz Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO2000076551A2 (en) * 1999-06-09 2000-12-21 Ktb Tumorforschungs Gmbh Method for producing an injectable medicament preparation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1156, no. 2, 1993, pages 151 - 160, ISSN: 0006-3002 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, DEMANT ERLAND J F ET AL: "Recognition of anthracycline binding domains in bovine serum albumin and design of a free fatty acid sensor protein.", XP002172298, Database accession no. PREV199395093150 *
DEMANT E J F ET AL: "CHARACTERIZATION OF THE COOPERATIVE CROSS-LINKING OF DOXORUBICIN N-HYDROXYSUCCINIMIDE ESTER DERIVATIVES TO WATER SOLUBLE PROTEINS", BIOCHIMICA ET BIOPHYSICA ACTA,NL,AMSTERDAM, vol. 1118, 1991, pages 83 - 90, XP002062905, ISSN: 0006-3002 *
KRATZ F ET AL: "A NOVEL MACROMOLECULAR PRODRUG CONCEPT EXPLOITING ENDOGENOUS SERUM ALBUMIN AS A DRUG CARRIER FOR CANCER CHEMOTHERAPY", JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 43, 6 April 2000 (2000-04-06), pages 1253 - 1256, XP000990088, ISSN: 0022-2623 *
KRATZ F ET AL: "PREPARATION, CHARACTERIZATION AND IN VITRO EFFICACY OF ALBUMIN CONJUGATES OF DOXORUBICIN", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN),PHARMACEUTICAL SOCIETY OF JAPAN,JP, vol. 21, no. 1, 1998, pages 56 - 61, XP000738275, ISSN: 0918-6158 *
PATENT ABSTRACTS OF JAPAN vol. 011, no. 365 (C - 460) 27 November 1987 (1987-11-27) *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 516 (C - 656) 17 November 1989 (1989-11-17) *

Also Published As

Publication number Publication date
JP2003508502A (en) 2003-03-04
WO2001017568A2 (en) 2001-03-15
EP1212120A2 (en) 2002-06-12
WO2001017614A2 (en) 2001-03-15
AU2005203768A1 (en) 2005-09-15
CA2383794A1 (en) 2001-03-15
AU7440400A (en) 2001-04-10
AU7440600A (en) 2001-04-10
JP2003508501A (en) 2003-03-04
EP1235618A2 (en) 2002-09-04
WO2001017568A3 (en) 2002-07-11
AU781380B2 (en) 2005-05-19
CA2383798A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
AU2001262153A1 (en) Pyrrole-2,5-dione derivatives for the treatment of diabetes
EP2348024A3 (en) Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
AU1393000A (en) 1,4-diazabicyclo(3.2.2)nonane derivatives, their preparation and therapeutic application
WO2003035617A3 (en) Derivatives of uk-2a
AU2002238947A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
WO2002074042A3 (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
WO2002060894A3 (en) Sulfonamide lactam inhibitors of factor xa
WO2003029420A3 (en) Apo-2 ligand variants and uses thereof
AU2984000A (en) Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same
IL137365A0 (en) Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2003084926A3 (en) Polymeric acyl derivatives of indoles
WO2001019826A3 (en) Triazolopyrimidine derivatives
AU3883800A (en) Hob-bp2h compositions, methods and uses thereof
AU2001270310A1 (en) Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
AU7881800A (en) Epicyclic stage
AU6394500A (en) Native cdc25 substrates, compositions and uses related thereto
AU4129800A (en) Bis-benzazoles and their use as antineoplastic agents
EP1889639A3 (en) Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
AU2002235883A1 (en) 2-heteroaryl-3,4-dihydro-2H-pyrrole derivatives and the use thereof as pesticides
AU2002316617A1 (en) Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
AU2001240543A1 (en) Cytostatic agent glycoconjugate
AU5714700A (en) Cvt/ivt component
IL156861A0 (en) Pyrrole derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
AU5714800A (en) Ivt component
AU2002332286A1 (en) Water-soluble phenylpyridazine derivatives and medicines containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000962764

Country of ref document: EP

Ref document number: 2383794

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 521398

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 74404/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000962764

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642